Crossmark

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma

Crossref DOI link: https://doi.org/10.1186/s12967-016-0857-1

Published Online: 2016-05-03

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

De Divitiis, C.

von Arx, C.

Grimaldi, A. M.

Cicala, D.

Tatangelo, F.

Arcella, A.

Romano, G. M.

Simeone, E.

Iaffaioli, R. V.

Ascierto, P. A.

Tafuto, S.